Last $6.79 USD
Change Today +0.359 / 5.58%
Volume 929.2K
ARWR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:49 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

arrowhead research corp (ARWR) Snapshot

Open
$6.37
Previous Close
$6.43
Day High
$6.79
Day Low
$6.35
52 Week High
03/6/14 - $27.63
52 Week Low
12/4/14 - $4.95
Market Cap
371.6M
Average Volume 10 Days
3.3M
EPS TTM
$-1.21
Shares Outstanding
54.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARROWHEAD RESEARCH CORP (ARWR)

Related News

No related news articles were found.

arrowhead research corp (ARWR) Related Businessweek News

No Related Businessweek News Found

arrowhead research corp (ARWR) Details

Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology include Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types. The company is also involved in the development of Adipotide, which is in phase I clinical trial for the treatment of obesity and metabolic disorders; and CRLX-101 that is in phase II clinical trial to treat various cancer types, including relapsed renal cell carcinoma, relapsed ovarian cancer, and non-metastatic rectal cancer. It has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates. The company was formerly known as InterActive Group, Inc. Arrowhead Research Corporation was incorporated in 1989 and is headquartered in Pasadena, California.

81 Employees
Last Reported Date: 11/25/14
Founded in 1989

arrowhead research corp (ARWR) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $579.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $305.1K
Chief Operating Officer and Head of R&D
Total Annual Compensation: $417.5K
Compensation as of Fiscal Year 2013.

arrowhead research corp (ARWR) Key Developments

Arrowhead Research Corp. to Amend and Restate the Company’s Certificate of Incorporation

Arrowhead Research Corp. announced that it will approve a proposal to amend and restate the Company’s Certificate of Incorporation to divide the company's Board of Directors into three classes, with directors in each class serving staggered three-year terms at the 2015 Annual Meeting of Stockholders to be held on March 3, 2015.

Gilead Sciences Reportedly May Acquire Arrowhead Research

Gilead Sciences Inc. (NasdaqGS:GILD) reportedly is planning to acquire Arrowhead Research Corp. (NasdaqGS:ARWR). Gilead is primarily interested in Arrowhead's Hepatitis B experimental RNAi drug, ARC-520, according to multiple sources including Seeking Alpha and BioSpace.

Arrowhead Research Corp. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Arrowhead Research Corp. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARWR:US $6.79 USD +0.359

ARWR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARWR.
View Industry Companies
 

Industry Analysis

ARWR

Industry Average

Valuation ARWR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,985.5x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,125.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARROWHEAD RESEARCH CORP, please visit www.arrowheadresearch.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.